COVAXIN Archives - Maritime Shipping News

Indian Covid Vaccine Shows 78% Efficacy Against Most Variants

23 April 2021

Indian Covid vaccine shot showed 78% efficacy against severe reactions and most of the Covid variants, says an article published in Bloomberg Quint.

Covaxin

Covaxin, a two-shot injection that uses an inactivated or dead form the virus, also showed 100% efficacy at preventing severe symptoms and hospitalizations against the coronavirus. The vaccine was made at Bharat Biotech International Ltd. and the Indian Council for Medical Research.

Director general of the Indian Council of Medical Research...

https://mfame.guru/indian-covid-vaccine-shows-78-efficacy-against-most-variants/

Indian Funds Its Vaccine Manufacturers With $610 million

21 April 2021

India’s government has approved a 45.67-billion-rupee ($610 million) grant for COVID-19 vaccine makers Serum Institute of India (SII) and Bharat Biotech to boost production capacity, says an article published in Reuters.

Serum Institute of India

SII, the world’s biggest maker of vaccines including the AstraZeneca shot, is funded with 30 billion rupees ($400 million).

SII sought the funds to increase its monthly capacity to more than 100 million doses by the end of May, from up to 70 million...

https://mfame.guru/indian-funds-610-million-to-its-vaccine-manufacturers/

Alternative To Oxford-AstraZeneca Vaccine

10 April 2021

AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine has recently dominated headlines after cases of rare blood clots were reported in European countries. Now, European Medical Agency (EMA) is investigating potential clotting risks from Johnson & Johnson’s (NYSE: JNJ) one-shot COVID-19 vaccine, reports Yahoo Finance.

What Happened?

While AstraZeneca has been caught in a frenzy over possible links to rare blood clots and subsequent restriction on the usage of its vaccine, this is a formal disclosure...

https://mfame.guru/alternative-to-oxford-astrazeneca-vaccine/

Covaxin Is Safe With No Serious Side Effects, Says Leading Medical Journal

11 March 2021

Covaxin, India’s first indigenous vaccine for Covid-19, is “safe, immunogenic with no serious side effects”, says leading medical journal The Lancet in its interim efficacy analysis, says an article published in Economic Times.

Vaccine’s Phase 2 results

The Lancet – Infectious Diseases Journal, published phase 2 results of the vaccine developed by Hyderabad-based Bharat Biotech.

However, the report made it clear that efficacy cannot be determined by phase 2 trials and this required further...

https://mfame.guru/covaxin-is-safe-with-no-serious-side-effects-says-leading-medical-journal/

First Indian COVID-19 Vaccine To Enter Human Trials

30 June 2020

India’s first COVID-19 vaccine candidate approved for human trials.
The DCGI has approved the company’s application to conduct a Phase I and II clinical trial of Covaxin, which was developed along with the ICMR’s National Institute of Virology.
Human clinical trials are scheduled to start across the country in July for the vaccine.

Bharat Biotech’s COVID-19 vaccine has been approved for human trials, making it India’s first domestic candidate to get the green light from the government’s drug...

https://mfame.guru/first-indian-covid-19-vaccine-to-enter-human-trials/